134 results
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
30 May 24
SAB Biotherapeutics Announces Departure of Chief Financial Officer
6:49pm
statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Forward-looking statements generally
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
21 May 24
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
7:30am
facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation
8-K
EX-99.1
fdvbdx pnfa4iif9ptkh
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
8-K
EX-1.1
kgek3b7h4dbcticgkhs8
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
424B5
p173tkk602mga81ue
26 Jan 24
Prospectus supplement for primary offering
4:00pm
8-K
EX-99.1
dcscf491ljt vw
25 Jan 24
Other Events
5:00pm
8-K
6lah11ypv0654t4mticm
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
EX-99.1
x5d95
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
EX-99.1
546m y4k0ug99l1ktdob
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
5omk5d5xvr8
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
EX-99.1
2twsza3pxa t0ioh
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
8-K
EX-99.1
ub87nf07e7tuprql8is
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
8-K
EX-10.1
7gxz52
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
POS AM
hwusv7emzi
10 Jul 23
Prospectus update (post-effective amendment)
5:19pm